Griseofulvin (Griseofulvin, Microsize) Patent Expiration, LOE Window & CMS Spending

Griseofulvin (Griseofulvin, Microsize) by Cosette Pharmac: Off-Patent Genericized (AB Competition), 7 AB generics, $15.4M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCosette Pharmac
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors7
2024 CMS Total Public Spend$15.4M
2024 Medicare Part D Spend$1.3M
2024 Medicaid Spend$14.2M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 278.9% 2-yr change)